What are the main discrepancies between MM treating centers in Brazil?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paulo, BR. We asked, What are the main discrepancies between multiple myeloma (MM) treating centers in Brazil?

In this podcast, Hungria discusses their poster presented at ASH 2022 entitled: A Brazilian real-life experience of multiple myeloma patients: Final results from the Mmybrave multi-center study.

In particular, Hungria discusses the setting of this research, looking at the differences in the characteristics and overall survival of patients with MM in Brazil, considering the treatment center type, i.e., public or private institutions. Hungria considers the difference in access to drugs and the implications this may have on patients, and concludes by looking to the future for the improvement of treatment for all patients with MM in Brazil.

To find out more about this research study, read the Multiple Myeloma Hub summary here.

Hosted on Acast. See acast.com/privacy for more information.